CMS advises Takeda on deal worth EUR 9.6 billion

25/05/2011

CMS has successfully advised Takeda Pharmaceutical on its EUR 9.6 billion acquisition of the globally active drug company Nycomed. This is one of the most significant M&A transactions to occur in the lifesciences sector this year.

Publication
CMS advises Takeda on deal worth EUR 9.6 billion
Download
DOCX 238.6 kB

Related people

Picture of Peter Huber
Peter Huber
Managing Partner